Literature DB >> 4053265

Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.

L Pendyala, S Madajewicz, S B Lele, S G Arbuck, P J Creaven.   

Abstract

Levels of three enzymes, leucine aminopeptidase (LAP), N-acetyl-beta-D-glucosaminidase (NAG), and beta-glucuronidase (BGA) were measured in the urine of patients receiving hematologically toxic doses of iproplatin (a) with or (b) without pretreatment hydration. The maximum post-treatment increases in the levels of each of the enzymes were compared between these two groups of patients. In addition, the maximum increases in urinary enzyme levels in iproplatin-treated patients were compared with those in patients treated with 40 mg/m2 cisplatin, a known nephrotoxic agent. Increases in LAP levels after cisplatin treatment in the periods studied are significantly higher than those after iproplatin treatment (P less than 0.05). No differences were found in the increases in BGA and NAG levels between iproplatin treatment and cisplatin treatment. No differences were found in the increases in levels of any of the enzymes between patients receiving iproplatin with pretreatment hydration and no prior hydration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053265     DOI: 10.1007/BF00263886

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

Review 1.  Diagnostic value of urinary enzyme determinations.

Authors:  W P Raab
Journal:  Clin Chem       Date:  1972-01       Impact factor: 8.327

Review 2.  Urinary enzymes, nephrotoxicity and renal disease.

Authors:  R G Price
Journal:  Toxicology       Date:  1982       Impact factor: 4.221

3.  Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum.

Authors:  U Diener; E Knoll; B Langer; H Rautenstrauch; D Ratge; H Wisser
Journal:  Clin Chim Acta       Date:  1981-05-05       Impact factor: 3.786

4.  Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase.

Authors:  J A Kuhn; W P Argy; T A Rakowski; J K Moriarty; G E Schreiner; P S Schein
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

5.  Renal complications of cis-diamminedichloroplatinum.

Authors:  R Nitschke
Journal:  Ann Clin Lab Sci       Date:  1981 Sep-Oct       Impact factor: 1.256

6.  Comparison of methods of evaluating nephrotoxicity of cis-platinum.

Authors:  B R Jones; R B Bhalla; J Mladek; R N Kaleya; R J Gralla; N W Alcock; M K Schwartz; C W Young; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

7.  Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP).

Authors:  P J Creaven; S Madajewicz; L Pendyala; A Mittelman; E Pontes; M Spaulding; S Arbuck; J Solomon
Journal:  Cancer Treat Rep       Date:  1983-09

8.  Nephrotoxicity of cis-platinum (II) dichlorodiammine.

Authors:  J J Stark; S B Howel
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

Review 9.  Minireview. The nephrotoxicity of cisplatin.

Authors:  R S Goldstein; G H Mayor
Journal:  Life Sci       Date:  1983-02-14       Impact factor: 5.037

10.  Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man.

Authors:  M Dentino; F C Luft; M N Yum; S D Williams; L H Einhorn
Journal:  Cancer       Date:  1978-04       Impact factor: 6.860

View more
  6 in total

1.  Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma.

Authors:  N J Petrelli; P J Creaven; L Herrera; A Mittelman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.

Authors:  C Ewen; A Perera; J H Hendry; C A McAuliffe; H Sharma; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).

Authors:  A W Skillen; P K Buamah; B M Cantwell; C Cornell; A W Hodson; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.

Authors:  M P Goren; A A Forastiere; R K Wright; M E Horowitz; R K Dodge; B A Kamen; M J Viar; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (iproplatinum, CHIP) in patients with normal and impaired renal function and following intraperitoneal administration.

Authors:  D J Kerr; M Harding; J G Farmer; J Amarin; R G Blackie; S J Harland; S B Kaye
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

6.  Cumulative renal tubular damage associated with cisplatin nephrotoxicity.

Authors:  M P Goren; R K Wright; M E Horowitz
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.